{"nctId":"NCT03337542","briefTitle":"AR101 Real-World Open-Label Extension Study","startDateStruct":{"date":"2017-10-18","type":"ACTUAL"},"conditions":["Peanut Allergy"],"count":243,"armGroups":[{"label":"Treatment arm description","type":"OTHER","interventionNames":["Biological: AR101"]}],"interventions":[{"name":"AR101","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Received AR101 in study ARC007\n* Completed the ARC007 study\n* Use of effective birth control by sexually active female subjects of childbearing potential\n\nKey Exclusion Criteria:\n\n* Developed a clinically significant change in health status during the ARC007 study which in the opinion of the investigator would make the subject unsuitable for participation in this study.\n* Receiving a prohibited medication or anticipated use of a prohibited medication \\[e.g., angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers or calcium channel blockers\\], any monoclonal antibody, any investigational peanut immunotherapy, or any other immunomodulatory therapy.\n* Currently in the build-up phase of immunotherapy for any nonfood allergen.\n* Currently participating in any other interventional clinical study outside of the ARC007 study that was just completed.","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability)","description":"Number of participants with treatment-emergent adverse events including serious adverse events during the overall study period (safety and tolerability)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Premature Discontinuation of Dosing Due to Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Early Discontinuation of Dosing Due to Chronic/Recurrent GI Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Chronic/Recurrent GI Adverse Events Resolving Before 2, Between 2 and 4, Between 4 and 12, and â‰¥ 12 Weeks After Discontinuation of Dosing","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Allergic Hypersensitivity Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With of Anaphylaxis as Defined in the Protocol","description":"Anaphylaxis is likely when any 1 of the 3 following sets of criteria is fulfilled:\n\n1. Acute onset of an illness (minutes to hours) with involvement of: (a) Skin/mucosal tissue (eg, generalized hives, itch/flush, swollen lips/tongue/uvula); AND (b) Airway compromise (eg, dyspnea, stridor, wheeze/bronchospasm, hypoxia, reduced PEFR); AND/OR (c) Reduced BP or associated symptoms (eg, hypotonia, syncope, incontinence).\n2. Two or more of the following that occur rapidly after exposure to the allergen (minutes to hours): (a) Skin/mucosal tissue; (b) Airway compromise; (c) Reduced BP or associated symptoms; (d) Persistent GI symptoms (eg, nausea, vomiting, crampy abdominal pain).\n3. Reduced BP after exposure to the allergen (minutes to hours). Infants and children: low systolic BP (age-specific) or \\> 30% drop in systolic BP; Adults: systolic BP \\< 90 mm Hg or \\> 30% drop from their baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Epinephrine Use as Rescue Medication","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Accidental/Nonaccidental Ingestion of Peanut and Other Allergenic Foods","description":"Number of participants with accidental/nonaccidental ingestion of peanut (not AR101 or food challenge material) and other allergenic foods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Asthma Control Using the Childhood Asthma Control Test (C-ACT) Questionnaire Total Score From Baseline, Every 4 Weeks, Early Discontinuation and Study Exit, Ages 4-11","description":"The C-ACT for subjects aged 4 to 11 years included 4 questions for the subject and 3 questions for the parent/caregiver; the total score (sum of 7 questions) ranged from 0 (worst control) to 27 (total control).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":"2.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":"2.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":"1.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":"2.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.3","spread":"1.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":"2.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.9","spread":"2.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":"3.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"2.94"}]}]}]},{"type":"SECONDARY","title":"Assessment of Asthma Control Using the Asthma Control Test (ACT) Questionnaire Total Score From Baseline, Every 4 Weeks, Early Discontinuation and Study Exit, Ages 12-17","description":"The ACT for subjects aged 12 to 17 years consisted of 5 questions, and the total score (sum of 5 questions) ranged from 5 (worst control) to 25 (total control).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":"1.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":"1.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":"1.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":"2.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":"2.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.6","spread":"2.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":"2.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":"4.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":"2.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.68"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events That Led to Early Withdrawal","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":242},"commonTop":["Cough","Abdominal discomfort","Throat irritation","Upper respiratory tract infection","Pruritus"]}}}